Name
Follicular lymphoma, grade 2
ICD-O-3 Morphology
9691/3: Follicular lymphoma, grade 2
Effective
2001 and later
Reportable
for cases diagnosed
1978 and later
Primary Site(s)
See Module 7
Most common sites of involvement: lymph nodes, Waldeyer ring, skin, duodenum, ocular adnexa, breast and testis.
Common metastatic sites include the bone marrow/peripheral blood.
Spleen involvement is common due to dissemination of disease
See abstractor notes
Common metastatic sites include the bone marrow/peripheral blood.
Spleen involvement is common due to dissemination of disease
See abstractor notes
Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
Follicular lymphoma, grade 2 is part of the Mature B-cell neoplasms lineage table in the WHO 5th edition of Hematolymphoid Tumors. (See Appendix B in the Hematopoietic Manual, Table B15)
There are several follicular lymphoma subtypes
1. Follicular lymphoma, NOS (9690/3)
2. Follicular lymphoma, grade 1 (9695/3)
3. Follicular lymphoma, grade 2 (9691/3)
4. Follicular lymphoma, grade 3, 3A, 3B (9698/3)
5. Duodenal-type follicular lymphoma (9695/3)
6. Large B-cell lymphoma with IRF4 rearrangement (9698/3)
7. Pediatric-type follicular lymphoma. (9695/3)
Code 9691/3 if a pathology report or physician documents "Follicular lymphoma, grade 1-2"
Follicular lymphomas are always the same primary. When there are multiple diagnoses of Follicular lymphoma, update the histology (as needed) to always reflect the highest grade. Known grade always takes priority over the NOS histology. (See Rule M2 in the Hematopoietic manual).
Priority order:
1. 9698/3: Follicular lymphoma, Grade 3, 3A, 3B
2. 9691/3: Follicular lymphoma, Grade 2
3. 9695/3: Follicular lymphoma, Grade 1
4. 9690/3: Follicular lymphoma, NOS
Most patients have widespread disease at diagnosis, including peripheral and central (abdominal and thoracic) lymphadenopathy and splenomegaly. Most patients present with peripheral lymphadenopathy, but any nodal group can be involved. A pure extranodal presentation is uncommon but can occur in almost any extranodal site.
When any area of diffuse large-B-cell lymphoma (DLBCL) is present in a FL the disease should be reported as diffuse large B-cell lymphoma (9680/3) (See M4, PH15).
There are several follicular lymphoma subtypes
1. Follicular lymphoma, NOS (9690/3)
2. Follicular lymphoma, grade 1 (9695/3)
3. Follicular lymphoma, grade 2 (9691/3)
4. Follicular lymphoma, grade 3, 3A, 3B (9698/3)
5. Duodenal-type follicular lymphoma (9695/3)
6. Large B-cell lymphoma with IRF4 rearrangement (9698/3)
7. Pediatric-type follicular lymphoma. (9695/3)
Code 9691/3 if a pathology report or physician documents "Follicular lymphoma, grade 1-2"
Follicular lymphomas are always the same primary. When there are multiple diagnoses of Follicular lymphoma, update the histology (as needed) to always reflect the highest grade. Known grade always takes priority over the NOS histology. (See Rule M2 in the Hematopoietic manual).
Priority order:
1. 9698/3: Follicular lymphoma, Grade 3, 3A, 3B
2. 9691/3: Follicular lymphoma, Grade 2
3. 9695/3: Follicular lymphoma, Grade 1
4. 9690/3: Follicular lymphoma, NOS
Most patients have widespread disease at diagnosis, including peripheral and central (abdominal and thoracic) lymphadenopathy and splenomegaly. Most patients present with peripheral lymphadenopathy, but any nodal group can be involved. A pure extranodal presentation is uncommon but can occur in almost any extranodal site.
When any area of diffuse large-B-cell lymphoma (DLBCL) is present in a FL the disease should be reported as diffuse large B-cell lymphoma (9680/3) (See M4, PH15).
Diagnostic Confirmation
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
Module Rule
None
Alternate Names
Definition
Follicular lymphoma (FL) is a neoplasm of germinal-center (GC) B cells with varying proportions of centrocytes and centroblasts or large transformed cells and at least a partially follicular growth pattern. In rare cases with an entirely diffuse growth pattern, the neoplastic cells should still show GC B-cell morphology and immunophenotype.
Definitive Diagnostic Methods
Cytogenetics
Genetic testing
Histologic confirmation
Immunohistochemistry
Immunophenotyping
Genetics Data
Immunophenotyping
BCL6+ (expression/positive)
CD10+ (expression/positive)
GCET1+ (expression/positive)
GCET2 (HGAL) positive
LMO2+ (expression/positive)
MEF2B+ (expression/positive)
Treatments
Chemotherapy
Hematologic Transplant and/or Endocrine Procedures
Immunotherapy
Radiation therapy
Transformations to
Transformations from
None
Same Primaries
Corresponding ICD-10 Codes (Cause of Death codes only)
C82.1 Non-Hodgkin lymphoma mixed small cleaved and large cell, follicular
Corresponding ICD-10-CM Codes (U.S. only)
C82.1_ Follicular lymphoma grade II (effective October 01, 2015)
C82.1A Follicular lymphoma grade II, in remission (effective October 01, 2015)
Signs and Symptoms
Drenching night sweats
Fatigue
Fever (or no known reason)
Lymphadenopathy (abdominal and thoracic)
Pain in chest, abdomen or bones (for no known reason)
Skin rash or itchy skin
Splenomegaly
Weight loss (for no known reason)
Diagnostic Exams
Blood chemistry studies
Bone marrow aspiration and biopsy
Cytogenetics studies
CT (CAT) scan
Flow cytometry
Immunohistochemistry
Immunophenotyping
Laparoscopy (rarely performed)
Laparotomy (rarely performed)
Lymph node biopsy
Progression and Transformation
25-35% of patients transform to DLBCL
Epidemiology and Mortality
Age: 60 years median age (rare occurrence under 20 years of age)
Incidence: Follicular lymphomas account for 20% of all lymhpomas
Sex: slight female predominance
Survival: 8-15 years median survival, closely related to the extent of the disease at diagnosis
Sources
International Classification of Diseases for Oncology, 3rd edition (including revisions). Geneva: World Health Organization, 2001, 2011, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
PDQ® Adult Treatment Editorial Board. PDQ Indolent B-Cell Non-Hodgkin Lymphoma Treatment. Bethesda, MD: National Cancer Institute. Updated <02/18/2025>. Available at: https://www.cancer.gov/types/lymphoma/hp/indolent-b-cell-lymphoma-treatment-pdq. Accessed <03/04/2025>. [PMID: 37437080]
Section: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
Pages: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq
Section: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
Pages: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Mature B-cell neoplasms
Pages: 266-281
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Mature B-cell neoplasms
Pages: 266-281
Home